H. Lee Moffitt Cancer Center & Research Institute

Physician, Faculty, and Staff

Rebecca Sutphen, MD

Rebecca Sutphen, MD

Titles:

Department/Program Affiliations:

  • Risk Assessment,Detection & Intervention  
  • Cancer Genetic Counseling & Testing  
  • Breast  
  • Gynecologic Oncology  
  • Lifetime Cancer Screening  

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

USF Affiliations/College Department:

  • Medicine / Interdisciplinary Oncology / Comprehensive Breast
  • Medicine / Pediatrics
  • Medicine / Interdisciplinary Oncology / Risk Assessment, Intervention & Detection
  • Medicine / Interdisciplinary Oncology / Gynecologic Oncology

University Academic Rank:

Associate Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Rebecca Sutphen, MD

Education & Training:

  • M.D., Temple University School of Medicine, Philadelphia, 1990
  • Residency, University of South Florida, 1993 - Pediatric
  • Fellowship, University of South Florida, 1996 - Human Genetics

General Board Certification / SubSpecialty:

  • Clinical Genetics
  • Pediatrics
  • Clinical Molecular Genetics
  • Clinical Cytogenetics

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Rebecca Sutphen, MD

Research Interests:

The focus of Dr. Sutphen's research is clinical cancer genetic epidemiology, specifically, heritable cancer risk, factors that modify heritable risk, and development of strategies to reduce risk and improve early cancer detection.

Dr. Sutphen's research focuses heavily on population-based ovarian cancer studies. Through a community-based regional rapid ascertainment network she established, Dr. Sutphen and her clinical colleagues identify and confirm all incident epithelial ovarian cancer cases in the Tampa-St. Petersburg-Clearwater region, with a population in excess of 2 million. Data from these ongoing efforts included the finding of a higher frequency of BRCA1 and BRCA2 mutations among women with invasive ovarian cancer than previously reported, and a higher contribution of BRCA2 to ovarian cancer than previously known. Dr. Sutphen is currently co-Investigator in a followup study to examine the contribution of mismatch repair deficiency genes to ovarian cancer.

Dr. Sutphen is also Co-PI of a unique new NCI-funded initiative to accomplish a genome-wide analysis to identify other genetic loci underlying ovarian cancer. This massive and unique effort led by Moffitt is being performed in collaboration with 4 other large, population-based studies of ovarian cancer in North America, encompassing 4000 ovarian cancer patients and 4000 healthy matched controls.

Dr. Sutphen's translational research also focuses on development of ovarian cancer biomarkers for early detection, accurate diagnosis and effective treatment. Current screening modalities available for ovarian cancer detection, including transvaginal ultrasounds and circulating levels of CA125, have not been shown to be effective in early detection of this disease. Other circulating biomarkers may have potential as a 'blood test' for early detection. A study conducted by Dr. Sutphen and her associates, 'Investigation of Lysophosphatidic Acid as a Biomarker in Ovarian Cancer,' provided promising preliminary results showing statistically significant differences in levels of several lysophospholipids between ovarian cancer patients and healthy controls. Current efforts are directed at validation of these findings in a larger study.

Dr. Sutphen is also currently leading a large NIH-funded study using state-of-the-art proteomics technology. The study is enrolling 1000 women undergoing surgery for suspected ovarian cancer, and analyzing their blood samples for proteomic markers which differ from proteins found in healthy women.



For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Rebecca Sutphen, MD

Publications:

  1. Permuth-Wey J, Boulware D, Valkov N, Livingston S, Nicosia S, Lee JH, Sutphen R, Schildkraut J, Narod S, Parker A, Coppola D, Sellers T, Pal T. Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):28-34. Pubmedid: 19124477.   Pubmed ID: 19124477

  2. Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, Majzoub K, Rivas GE, Alluin J, Rossi JJ, Krontiris TG, Weitzel J, Daly MB, Benson AB, Kirkwood JM, O'Dwyer PJ, Sutphen R, Stewart JA, Johnson D, Larson GP. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res. 2009 Sep;69(18):7459-7465. Pubmedid: 19738052. Pmcid: PMC2747041.   Pubmed ID: 19738052

  3. Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Mol Cell Proteomics. 2008 Oct;7(10):1780-1794. Pubmedid: 18664563.   Pubmed ID: 18664563

  4. Sellers T, Huang Y, Cunningham J, Goode E, Sutphen R, Vierkant R, KelemenLE, Fredericksen Z, Liebow M, Pankratz V, Hartmann L, Myer J, Iversen ES J, Schildkraut J, Phelan C. Association of single nucleotide polymorphisms in glycosylation genes with riskof epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):397-404. Pubmedid: 18268124.   Pubmed ID: 18268124

  5. Carvalho M, Marsillac S, Karchin R, Manoukian S, Grist S, Swaby R, Urmenyi T, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, Pickard-Brzosowicz J, Nathanson K, Sali A, Goldgar D, Couch F, Radice P, Monteiro A. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 2007 Feb;67(4):1494-1501. Pubmedid: 17308087.   Pubmed ID: 17308087

  6. Pal T, Napierala D, Becker T, Loscalzo M, Baldridge D, Lee B, Sutphen R. The presence of germ line mosaicism in cleidocranial dysplasia. Clin Genet. 2007 Jun;71(6):589-591. Pubmedid: 17539909.   Pubmed ID: 17539909

  7. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer. 2007 Jan;6(1):9-119. Pubmedid: 17160431.   Pubmed ID: 17160431

  8. Daly M, Axilbund J, Bryant E, Buys S, Eng C, Friedman S, Esserman L, Farrell C, Ford J, Garber J, Jeter J, Kohlmann W, Lynch P, Marcom P, Nabell L, Offit K, Osarogiagbon R, Pasche B, Reiser G, Sutphen R, Weitzel J. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2006 Feb;4(2):156-176. Pubmedid: 16451772.   Pubmed ID: 16451772

  9. Lancaster J, Dressman H, Clarke J, Sayer R, Martino M, Cragun J, Henriott A, Gray J, Sutphen R, Elahi A, Whitaker R, West M, Marks J, NevinsJR, Berchuck A. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer. 2006 Sep;16(5):1733-1745. Pubmedid: 17009964.   Pubmed ID: 17009964

  10. Freeman S, Bepler G, Haura E, Sutphen R, Cress W. Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst. 2005 Jul;97(14):1088-9. Pubmedid: 16030308.   Pubmed ID: 16030308

  11. Larson G, Ding Y, Cheng L, Lundberg C, Gagalang V, Rivas G, Geller L, Weitzel J, MacDonald D, Archambeau J, Slater J, Neuberg D, Daly M, Angel I, Benson A, Smith K, Kirkwood J, O'Dwyer P, Raskay B, Sutphen R, Drew R, Stewart J, Wendli J, Johnson D, Krontiris T, Ruckdeschel J. Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. Cancer Res. 2005 Feb;65(3):805-814. Pubmedid: 15705877.   Pubmed ID: 15705877

  12. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005 Dec;104(12):2807-2816. Pubmedid: 16284991.   Pubmed ID: 16284991

  13. Seballos L, Zhang J, Sutphen R. Surface-enhanced Raman scattering detection of lysophosphatidic acid. Anal Bioanal Chem. 2005 Nov;383(5):763-767. Pubmedid: 16261318.   Pubmed ID: 16261318

  14. Pal T, Permuth-Wey J, Holtje T, Sutphen R. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1794-1799. Pubmedid: 15533909.   Pubmed ID: 15533909

  15. Pal T, Sutphen R, Sellers T. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 2004;100(11):2485-2486. Pubmedid: 15160358.   Pubmed ID: 15160358

  16. Sutphen R, Xu Y, Wilbanks G, Fiorica J, Grendys EC, LaPolla J, Arango H, Hoffman M, Martino M, Wakeley K, Griffin D, Blanco R, Cantor A, Xiao Y, Krischer J. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(7):1185-1191. Pubmedid: 15247129.   Pubmed ID: 15247129

  17. Helm J, Choi J, Sutphen R, Barthel J, Albrecht T, Chirikos T. Current and evolving strategies for colorectal cancer screening. Cancer Control. 2003;10(3):193-204. Pubmedid: 12794617.   Pubmed ID: 12794617

  18. Herman G, Kelley R, Pureza V, Smith D, Kopacz K, Pitt J, Sutphen R, Sheffield L, Metzenberg A. Characterization of mutations in 22 females with X-linked dominant chondrodysplasia punctata (Happle syndrome). Genet Med. 2002;4(6):434-438. Pubmedid: 12509714.   Pubmed ID: 12509714

  19. Schurman S, Perlman S, Sutphen R, Campos A, Garin E, Cruz D, Shoemaker L. Genotype/phenotype observations in African Americans with Bartter syndrome. J Pediatr. 2001;139(1):105-110. Pubmedid: 11445802.   Pubmed ID: 11445802

  20. Ferlita T, Sutphen R, Tabano M, Fiorica J. Introduction to hereditary breast and ovarian cancer. Oper Tech Gyn Surg. 2000;5(3):183-189. Pubmedid: noPMID.  

  21. Bamshad M, Le T, Watkins W, Dixon M, Kramer B, Roeder A, Carey J, Root S, Schinzel A, Van Maldergem L, Gardener R, Lin R, Seidman C, Seidman J, Wallerstein R, Moran E, Sutphen R, Campbell C, Jorde L. The spectrum of mutations in TBX3: Genotype/Phenotype relationship in ulnar-mammary syndrome. Am J Hum Genet. 1999;64(6):1550-1562. Pubmedid: 10330342.   Pubmed ID: 10330342

  22. Daly M, Angelos P, Bryant E, Buys S, Eng C, Engstrom P, Farrell C, Garber J, Graham J, Greely H, Gruber S, Helzlsouer K, Knight S, Koopamn C, Lynch P, Nabell L, Offit K, Petersen G, Reiser G, Reiger P, Sutphen R, Weitzel J. NCCN practice guidelines: genetics/familial high-risk cancer screening. Oncology. 1999;13(11A):161-212. Pubmedid: noPMID.  

  23. Nowak K, Wattanasirichaigon D, Goebel H, Wilce M, Pelin K, Donner K, Jacob R, Hubner C, Anderson J, North K, Iannaccone S, Muller C, Numberg P, Muntoni F, Hughes I, Sutphen R, Lacson A, Vigneron J, Wallgren C, Beggs A, Laing N. Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet. 1999;23(2):208-212. Pubmedid: 10508519.   Pubmed ID: 10508519

  24. Sutphen R, Diamond T, Minton S, Peacocke M, Root A. Severe Lhermitte-Duclos disease with unique germline mutation of PTEN. Am J Med Genet. 1999;82(4):290-293. Pubmedid: 10051160.   Pubmed ID: 10051160

  25. Diamond T, Sutphen R, Tabano M, Fiorica J. Inherited susceptibility to breast and ovarian cancer. Curr Opin Obstet Gynecol. 1998;10(1):3-8. Pubmedid: 9484622.   Pubmed ID: 9484622

  26. Frizell E, Sutphen R, Diamond F, Overhauser J. t(1;18)(q32.1;q22.1) associated with genitourinary malformations. Clin Genet. 1998;54(4):330-333. Pubmedid: 9831345.   Pubmed ID: 9831345

  27. Tsou H, Ping X, Xiao X, Gruener A, Zhang H, Nini R, Swisshelm K, Sybert V, Diamond T, Sutphen R, Peacocke M. The genetic basis of Cowden's syndrome: three novel mutations in PTEN/MMAC/TEP1. Hum Genet. 1998;102(4):467-473. Pubmedid: 9600246.   Pubmed ID: 9600246

  28. Mueller O, Zeffren B, Sutphen R, Clayton D, Hinds-Frey K, Kousseff B, Kornfeld S. The extent of chromosome 22q11 deletions in DiGeorge and related syndromes: is there a correlation with phenotype?. Am J Hum Genet. 1996;59:A142-A142.  

  29. Sutphen R, Amar M, Kousseff B, Toomey K. XXY male with X-linked dominant chondrodysplasia punctata (Happle Syndrome). Am J Med Genet. 1995;57:489-492. Pubmedid: 7677157.   Pubmed ID: 7677157

  30. Sutphen R, Galan E, Kousseff B. Clitoromegaly in neurofibromatosis. Am J Med Genet. 1995;55:325-330. Pubmedid: 7726231.   Pubmed ID: 7726231

  31. Sutphen R, Galan-Gomez E, Cortada X, Newkirk P, Kousseff B. Tracheoesophageal anomalies in the oculoauriculovertebral (Goldenhar) spectrum. Clin Genet. 1995;48:66-71. Pubmedid: 7586653.   Pubmed ID: 7586653

  32. Artigas M, Haag M, Sutcliffe M, Dumont D, Saari J, Sutphen R, Kousseff B. 1997;277.  

  33. Diamond T, Sutphen R, Shaw G. 1997;A187.  

  34. Farag H, Kousseff B, Sutphen R. 1997;272.  

  35. Sutcliffe M, Sutphen R, Haag M, Tedesco T, Dumont D, Saari J, Tos T, Steele P, Diamond T, Moore J, Kousseff B. 1996;A134.  

  36. Sutphen R, Mueller O, Kousseff B. 1997;180.  

  37. Sutphen R. 1997;A114.  

Rebecca Sutphen, MD

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Florida Neurofibromatosis Research Network (NO COST EXTENSION)
Sponsor: Moffitt Fdtn / Thoresen Fdtn
Project Dates: January 1, 2005 to June 30, 2010

Project 2

5 U56 CA118809-04
Sponsor: Nat Institutes of Health / NCI
Project Dates: September 1, 2009 to August 31, 2010
Earned to Date: $74,459

Population-Based Analysis of Ovarian Cancer Biomarkers

5 R01 CA106414-05
Sponsor: Nat Institutes of Health / NCI
Project Dates: August 1, 2005 to May 31, 2010
Annual Direct Cost: $342,421
Annual Total Cost: $565,056
Project Total: $2,983,395

Physician/Faculty  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute